Acute mesenteric venous occlusion
ICD-10 K55.0 · ICD-11 DD30.2

Treatment of Acute Mesenteric Venous Thrombosis Presenting with Peritonitis

When acute mesenteric venous thrombosis is complicated by peritonitis or peritoneal signs at presentation, it signals progression of ischaemia that demands an urgent, structured clinical response distinct from uncomplicated cases.

Clinical scenario

Acute mesenteric venous thrombosis with peritonitis or peritoneal signs at presentation. Fever and peritoneal signs are suggestive of progression of ischaemia to bowel infarction, indicating that conservative management alone is insufficient.

Treatment approach — partial overview

Management in this setting centres on open surgical intervention aimed at removing irreversibly ischaemic bowel while preserving as much bowel as possible, combined with systemic anticoagulation and targeted supportive measures. Further steps in the algorithm — including sequencing, anticoagulation continuation strategy, and follow-up — are detailed in the full protocol.

Full regimen, sequencing, and clinical decision points available below …
Instant Access to Structured Evidence-Based Regimens
References
DOI: 10.1016/j.ejvs.2025.06.010
  • Peritonitis
  • Patients with persisting or worsening symptoms, organ failure, and those with perforation or signs of peritonitis require open surgical intervention.
  • Fever and peritoneal signs are suggestive of progression of ischaemia to bowel infarction.
  • The aim of surgery is to remove irreversibly ischaemic bowel and preserve as much bowel as possible.
  • Anticoagulation with unfractionated or low molecular weight heparin as first line therapy is recommended for all patients with acute mesenteric vein thrombosis.
  • Pain control, fluid and electrolyte supplementation, and bowel rest should be initiated immediately.
  • Anticoagulation for three to six months with a vitamin K antagonist or low molecular weight heparin is recommended for all patients with acute mesenteric vein thrombosis.
  • Anticoagulation for three to six months with a direct oral anticoagulant as an alternative to a vitamin K antagonist or low molecular weight heparin may be considered for all patients with acute mesenteric vein thrombosis.
View source ↗